Runben Biotechnology released its performance for the first three quarters, with a net profit attributable to the parent company of 266 million yuan, a year-on-year increase of 1.98%

According to the Zhitong Finance APP, Runben Biotechnology disclosed its third-quarter report for 2025. The company achieved revenue of 1.238 billion yuan in the first three quarters, a year-on-year increase of 19.28%; the net profit attributable to shareholders of the listed company was 266 million yuan, a year-on-year increase of 1.98%; the net profit excluding non-recurring gains and losses was 251 million yuan, a year-on-year decrease of 1.79%; the basic earnings per share were 0.66 yuan

Certain A Shares of Runben Biotechnology Co., Ltd. are subject to a Lock-Up Agreement Ending on 17-OCT-2025.

Runben Biotechnology Co., Ltd. has certain A Shares under a Lock-Up Agreement until 17-OCT-2025, lasting 739 days from 9-OCT-2023. Key stakeholders, including actual controllers and directors, have committed to not transferring their shares for 36 months post-listing. If share prices fall below the issuance price for 20 consecutive trading days within 6 months, the lock-up will extend by 6 months. After the lock-up, they can only transfer 25% of their shares annually while in office.

Runben Biotechnology 2025 Half-Year Equity Distribution: Cash Dividend of 0.2 Yuan per Share

Runben Biotechnology Co., Ltd. announced the distribution of equity for the first half of 2025, with a cash dividend of RMB 0.20 per share, totaling RMB 80,918,662.80. The equity registration date is September 17, and the ex-dividend date and cash dividend payment date is September 18. Individual shareholders holding shares for more than one year may be temporarily exempt from individual income tax, and the reduction price for some shareholders is adjusted to no less than RMB 16.60 per share. Shareholders can contact the securities department for inquiries

Runben Biotechnology released its performance for the first half of the year, with a net profit attributable to the parent company of 188 million yuan, an increase of 4.16%

Runben Biotechnology released its semi-annual report for 2025, with operating revenue of 895 million yuan, a year-on-year increase of 20.31%; net profit attributable to the parent company of 188 million yuan, a year-on-year increase of 4.16%. The net profit excluding non-recurring gains and losses was 177 million yuan, a year-on-year increase of 0.86%. The basic earnings per share were 0.46 yuan. The company launched more sunscreen products, expanded offline channels, and plans to distribute a cash dividend of 2.00 yuan for every 10 shares to all shareholders

This week's largest increase in margin financing balance: Runben Biotechnology margin financing balance: 326 million yuan, balance increase: 147.62%; SOKAN margin financing balance: 125 million yuan, balance increase: 103.81%